CAS: 2030-63-9; N,5-Bis(4-Chlorophenyl)-3-(Isopropylimino)-3,5-Dihydrophenazin-2-Amine

上下游产品

CAS号84803-71-4 1,5-bis(4-chlor...

硝基氯苯置于盐酸,Iron(III) Chloride,Sodium Thiosulfate Pentahydrate,二氧化硫脲体系中,用 乙醇,水 用作溶剂,20.0~180.0 °C,800.01 Kpa 条件下,反应 16.0H,反应生成氯苯吩嗪
参考文献:一种氯苯吩嗪的制备方法
标题:一种氯苯吩嗪的制备方法
摘要:本申请涉及药物领域,具体公开了一种氯苯吩嗪的制备方法,包括如下步骤:S1,将邻卤硝基苯和对氯苯胺进行亲核反应,得到中间体a;S2,将中间体a的硝基还原为氨基得到中间体b;S3,将中间体b在三氯化铁,水和浓盐酸作用下经脱氢环化得到吩嗪化合物中间体c;S4,将中间体c进行加成‑消除反应,干燥得到氯苯吩嗪;所述硝基还原为氨基具体为:将乙醇,中间体a混合后,加入水,加热至50‑70°C,Ph>=9时加入二氧化硫脲,反应至白色,然后离心,水洗至中性,干燥得中间体b;通过调节氯苯吩嗪的制备方法的各个参数,使得到的氯苯吩嗪的总收率优异,且具有较高的纯度.

专利信息

专利号:US-2024197774-A1
优先权日:2021-04-16
标 题:Synthesis of Antimicrobial PVP-coated Bismuth Nanoparticles
发明人：LOPEZ-RIBOT JOSE; VAZQUEZ-MUNOZ ROBERTO
权利人:UNIV TEXAS
摘要:Described herein is a facile, fast, and economical method for the synthesis of BAL-mediated PVP-BiNPs, using basic laboratory instruments and reagents readily available in most laboratories.

专利号:US-9845289-B2
优先权日:2014-08-01
标题 :Process for the synthesis of Dapsone and its intermediates
发明人：BARATELLA MARCO; CASTALDI GRAZIANO; CASTALDI MARTA; GABOARDI MAURO; PALLANZA GIUSEPPE
权利人:SEEGPHARM SA
摘要:A process for the synthesis of Dapsone and intermediates thereof are described.

专利号:US-10308663-B2
优先权日:2015-06-16
标题:Inhibitors of PTP4A3 for the treatment of cancer
发明人：LAZO JOHN S; SHARLOW ELIZABETH R; MCQUEENEY KELLEY E; WIPF PETER; SALAMOUN JOSEPH M
权利人:LAZO JOHN S; SHARLOW ELIZABETH R; MCQUEENEY KELLEY E; WIPF PETER; SALAMOUN JOSEPH M; UNIV VIRGINIA PATENT FOUNDATION; UNIV OF PITTSBURGH —OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
摘要:The invention provides protein tyrosine phosphatase inhibitor compounds, Their pharmaceutical compositions, uses, and methods of use, such as in the treatment of various cancers, and process for making the compounds. Also disclosed is an improved synthesis of protein tyrosine phosphatase inhibitor and precursor compound thienopyridone (5).

专利号:US-11744867-B2
优先权日:2017-02-14
标 题 :Modulation of microbial synthesis of 4-ethylphenol and 4-ethylphenyl sulfate in behavior and disease
发明人：NEEDHAM BRITTANY D; MAZMANIAN SARKIS K; SHARON GIL; FUNABASHI MASANORI; FISCHBACH MICHAEL A; HSIAO ELAINE Y; PATTERSON PAUL H
权利人:CALIFORNIA INST OF TECHN; UNIV CALIFORNIA
摘要:Some embodiments relate to genetically engineered bacterial strains for modulation of levels of the bacterial metabolite 4-ethylphenol (4EP) and its sulfated form, 4-ethylphenyl sulfate (4EPS). In some embodiments, the bacteria reduce or inhibit production of 4EP or 4EPS in the gut of a subject. The bacteria can ameliorate, delay the onset, or reduce the likelihood of one or more symptoms associated with anxiety and/or autism spectrum disorder (ASD) in the subject.

专利号:US-11649285-B2
优先权日:2016-08-03
标题 :Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
发明人：KALABOKIS VASSILIOS; WANG JINGHUA; WU GUOPING; BAZAN JOSE FERNANDO; VALLEY CHRISTOPHER CARLIN
权利人:BIO TECHNE CORP
摘要:The ligand for VISTA is identified (VSIG3) as well as the use of this ligand and receptor interaction in the identification or synthesis of a VSIG3 agonist or antagonist compounds, preferably antibodies, polypeptides and fusion proteins which agonize or antagonize the effects of VSIG3 and/or VISTA and/or the VSIG3/VISTA interaction. These antagonists may be used to suppress VSIG3/VISTA's suppressive effects on T cell immunity, and more particularly used in the treatment of cancer, or infectious disease. These agonist compounds may be used to potentiate or enhance VSIG3/VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity, such as in the treatment of autoimmunity, allergy or inflammatory conditions. Screening assays for identifying these agonists and antagonist compounds are also provided.

专利号:US-9890126-B2
优先权日:2012-04-24
标 题:Synthesis of novel inhibitors of isoprenoid biosynthesis (ISPF)
发明人：HAGEN TIMOTHY J; ZHANG ZHENG; LAZOWSKI ZACHARY; CLARE MICHAEL; BEGLEY DARREN W
权利人:UNIV NORTHERN ILLINOIS BOARD OF TRUSTEES; BERYLLIUM DISCOVERY CORP
摘要:Antibacterial and antimalarial IspF inhibitor compounds and compositions are described. Methods include administering described compounds and compositions to treat bacterial or parasitic infections and to inhibit parasite or bacterial growth.